블로그

• A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab Background: Adrixetinib (Q702) is an orally administrated novel Axl/Mer/CSF1R tyrosine kinase inhibitor The safety profile, pharmacokinetics (PK) and efficacy data for Q702 in combination with pembrolizumab blog.naver.com · 2025.06.03